Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge M W Verberk

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Scientific Reports|May 7, 2021
Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's diseaseElisabeth H Thijssen, Inge M W Verberk, Jeroen Vanbrabant, et al.
Journal of the American Heart Association|February 14, 2024
Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR StudyEmma L Twait, Lotte Gerritsen, Justine E F Moonen, et al.
Alzheimer'S Research & Therapy|April 14, 2025
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's diseaseSherif Bayoumy, Julie Goossens, Charlotte De Rocker, et al.
The Lancet. Neurology|November 28, 2021
Blood-based biomarkers for Alzheimer's disease: towards clinical implementationCharlotte E Teunissen, Inge M W Verberk, Elisabeth H Thijssen, et al.
Alzheimer'S Research & Therapy|October 11, 2024
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementiaLisa Le Scouarnec, Vincent Bouteloup, Pieter J van der Veere, et al.
Neurobiology of Aging|June 22, 2024
Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injurySuzan van Amerongen, Shreyasee Das, Suzie Kamps, et al.
Alzheimer'S Research & Therapy|January 16, 2021
Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive declineJulia Stockmann, Inge M W Verberk, Nina Timmesfeld, et al.
Clinical Chemistry and Laboratory Medicine|March 25, 2022
Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1Zoë Y G J van Lierop, Inge M W Verberk, Kees W J van Uffelen, et al.
Annals of Clinical and Translational Neurology|January 19, 2019
Serum Neurofilament light correlates with CADASIL disease severity and survivalGido Gravesteijn, Julie W Rutten, Inge M W Verberk, et al.
Alzheimer'S Research & Therapy|December 28, 2020
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive declineJulia Stockmann, Inge M W Verberk, Nina Timmesfeld, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Scientific Reports|May 7, 2021
Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's diseaseElisabeth H Thijssen, Inge M W Verberk, Jeroen Vanbrabant, et al.
Journal of the American Heart Association|February 14, 2024
Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR StudyEmma L Twait, Lotte Gerritsen, Justine E F Moonen, et al.
Alzheimer'S Research & Therapy|April 14, 2025
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's diseaseSherif Bayoumy, Julie Goossens, Charlotte De Rocker, et al.
The Lancet. Neurology|November 28, 2021
Blood-based biomarkers for Alzheimer's disease: towards clinical implementationCharlotte E Teunissen, Inge M W Verberk, Elisabeth H Thijssen, et al.
Alzheimer'S Research & Therapy|October 11, 2024
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementiaLisa Le Scouarnec, Vincent Bouteloup, Pieter J van der Veere, et al.
Neurobiology of Aging|June 22, 2024
Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injurySuzan van Amerongen, Shreyasee Das, Suzie Kamps, et al.
Alzheimer'S Research & Therapy|January 16, 2021
Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive declineJulia Stockmann, Inge M W Verberk, Nina Timmesfeld, et al.
Clinical Chemistry and Laboratory Medicine|March 25, 2022
Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1Zoë Y G J van Lierop, Inge M W Verberk, Kees W J van Uffelen, et al.
Annals of Clinical and Translational Neurology|January 19, 2019
Serum Neurofilament light correlates with CADASIL disease severity and survivalGido Gravesteijn, Julie W Rutten, Inge M W Verberk, et al.
Alzheimer'S Research & Therapy|December 28, 2020
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive declineJulia Stockmann, Inge M W Verberk, Nina Timmesfeld, et al.
Pageof 8